Truist Financial Forecasts Strong Price Appreciation for Humana (NYSE:HUM) Stock

Humana (NYSE:HUM) had its price objective lifted by Truist Financial from $290.00 to $325.00 in a research report report published on Friday,Benzinga reports. Truist Financial currently has a hold rating on the insurance provider’s stock.

HUM has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Wednesday, February 12th. Barclays upped their price objective on Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a report on Thursday, February 13th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $283.00 price target on shares of Humana in a research note on Wednesday, February 12th. Morgan Stanley decreased their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 12th. Finally, Piper Sandler upped their target price on shares of Humana from $270.00 to $288.00 and gave the company a “neutral” rating in a research report on Wednesday, January 15th. Seventeen analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, Humana has an average rating of “Hold” and a consensus price target of $288.60.

Humana Stock Performance

NYSE HUM opened at $294.97 on Friday. Humana has a 1-year low of $213.31 and a 1-year high of $406.46. The company has a 50 day moving average of $265.55 and a 200-day moving average of $270.65. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a market cap of $35.60 billion, a price-to-earnings ratio of 29.65, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, equities analysts forecast that Humana will post 16.47 earnings per share for the current fiscal year.

Humana Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Investors of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 annualized dividend and a yield of 1.20%. Humana’s dividend payout ratio is currently 35.58%.

Hedge Funds Weigh In On Humana

Large investors have recently added to or reduced their stakes in the company. Dodge & Cox boosted its position in shares of Humana by 106.7% during the fourth quarter. Dodge & Cox now owns 10,198,040 shares of the insurance provider’s stock worth $2,587,345,000 after buying an additional 5,264,045 shares during the period. Vanguard Group Inc. lifted its stake in Humana by 15.8% in the 4th quarter. Vanguard Group Inc. now owns 12,829,210 shares of the insurance provider’s stock valued at $3,254,899,000 after acquiring an additional 1,751,857 shares in the last quarter. Norges Bank acquired a new position in Humana during the 4th quarter worth approximately $416,202,000. Pzena Investment Management LLC grew its stake in shares of Humana by 44.0% during the 4th quarter. Pzena Investment Management LLC now owns 3,609,382 shares of the insurance provider’s stock worth $915,736,000 after acquiring an additional 1,103,132 shares in the last quarter. Finally, Boston Partners raised its holdings in shares of Humana by 435.8% in the fourth quarter. Boston Partners now owns 1,098,702 shares of the insurance provider’s stock valued at $279,236,000 after purchasing an additional 893,637 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.